These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

293 related articles for article (PubMed ID: 30253346)

  • 61. Small molecule inhibitors of cyclin-dependent kinase 9 for cancer therapy.
    Alsfouk A
    J Enzyme Inhib Med Chem; 2021 Dec; 36(1):693-706. PubMed ID: 33632038
    [TBL] [Abstract][Full Text] [Related]  

  • 62. CDKI-71, a novel CDK9 inhibitor, is preferentially cytotoxic to cancer cells compared to flavopiridol.
    Liu X; Shi S; Lam F; Pepper C; Fischer PM; Wang S
    Int J Cancer; 2012 Mar; 130(5):1216-26. PubMed ID: 21484792
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Cyclin-dependent kinase 9 is a novel specific molecular target in adult T-cell leukemia/lymphoma.
    Narita T; Ishida T; Ito A; Masaki A; Kinoshita S; Suzuki S; Takino H; Yoshida T; Ri M; Kusumoto S; Komatsu H; Imada K; Tanaka Y; Takaori-Kondo A; Inagaki H; Scholz A; Lienau P; Kuroda T; Ueda R; Iida S
    Blood; 2017 Aug; 130(9):1114-1124. PubMed ID: 28646117
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Identification of a potent 5-phenyl-thiazol-2-ylamine-based inhibitor of FLT3 with activity against drug resistance-conferring point mutations.
    Chen CT; Hsu JT; Lin WH; Lu CT; Yen SC; Hsu T; Huang YL; Song JS; Chen CH; Chou LH; Yen KJ; Chen CP; Kuo PC; Huang CL; Liu HE; Chao YS; Yeh TK; Jiaang WT
    Eur J Med Chem; 2015 Jul; 100():151-61. PubMed ID: 26081023
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Therapeutic Path to Triple Knockout: Investigating the Pan-inhibitory Mechanisms of AKT, CDK9, and TNKS2 by a Novel 2-phenylquinazolinone Derivative in Cancer Therapy- An
    Peters XQ; Elamin G; Aljoundi A; Alahmdi MI; Abo-Dya NE; Sidhom PA; Tawfeek AM; Ibrahim MAA; Soremekun O; Soliman MES
    Curr Pharm Biotechnol; 2024; 25(10):1288-1303. PubMed ID: 37581526
    [TBL] [Abstract][Full Text] [Related]  

  • 66. AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9.
    Cai D; Byth KF; Shapiro GI
    Cancer Res; 2006 Jan; 66(1):435-44. PubMed ID: 16397259
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor.
    Whittaker SR; Barlow C; Martin MP; Mancusi C; Wagner S; Self A; Barrie E; Te Poele R; Sharp S; Brown N; Wilson S; Jackson W; Fischer PM; Clarke PA; Walton MI; McDonald E; Blagg J; Noble M; Garrett MD; Workman P
    Mol Oncol; 2018 Mar; 12(3):287-304. PubMed ID: 29063678
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Discovery of novel indirubin-3'-monoxime derivatives as potent inhibitors against CDK2 and CDK9.
    Yan L; Lai F; Chen X; Xiao Z
    Bioorg Med Chem Lett; 2015 Jun; 25(11):2447-51. PubMed ID: 25908517
    [TBL] [Abstract][Full Text] [Related]  

  • 69. The discovery of Polo-like kinase 4 inhibitors: identification of (1R,2S).2-(3-((E).4-(((cis).2,6-dimethylmorpholino)methyl)styryl). 1H.indazol-6-yl)-5'-methoxyspiro[cyclopropane-1,3'-indolin]-2'-one (CFI-400945) as a potent, orally active antitumor agent.
    Sampson PB; Liu Y; Forrest B; Cumming G; Li SW; Patel NK; Edwards L; Laufer R; Feher M; Ban F; Awrey DE; Mao G; Plotnikova O; Hodgson R; Beletskaya I; Mason JM; Luo X; Nadeem V; Wei X; Kiarash R; Madeira B; Huang P; Mak TW; Pan G; Pauls HW
    J Med Chem; 2015 Jan; 58(1):147-69. PubMed ID: 25723005
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Efficacy of cyclin-dependent-kinase 9 inhibitors in a murine model of mixed-lineage leukemia.
    Garcia-Cuellar MP; Füller E; Mäthner E; Breitinger C; Hetzner K; Zeitlmann L; Borkhardt A; Slany RK
    Leukemia; 2014 Jul; 28(7):1427-35. PubMed ID: 24445865
    [TBL] [Abstract][Full Text] [Related]  

  • 71. A Selective and Orally Bioavailable Quinoline-6-Carbonitrile-Based Inhibitor of CDK8/19 Mediator Kinase with Tumor-Enriched Pharmacokinetics.
    Zhang L; Cheng C; Li J; Wang L; Chumanevich AA; Porter DC; Mindich A; Gorbunova S; Roninson IB; Chen M; McInnes C
    J Med Chem; 2022 Feb; 65(4):3420-3433. PubMed ID: 35114084
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Azole-based inhibitors of AKT/PKB for the treatment of cancer.
    Zeng Q; Allen JG; Bourbeau MP; Wang X; Yao G; Tadesse S; Rider JT; Yuan CC; Hong FT; Lee MR; Zhang S; Lofgren JA; Freeman DJ; Yang S; Li C; Tominey E; Huang X; Hoffman D; Yamane HK; Fotsch C; Dominguez C; Hungate R; Zhang X
    Bioorg Med Chem Lett; 2010 Mar; 20(5):1559-64. PubMed ID: 20137943
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Tetrahydro-3H-pyrazolo[4,3-a]phenanthridine-based CDK inhibitor.
    Opoku-Temeng C; Dayal N; Hernandez DE; Naganna N; Sintim HO
    Chem Commun (Camb); 2018 May; 54(36):4521-4524. PubMed ID: 29629444
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents.
    Shao H; Shi S; Foley DW; Lam F; Abbas AY; Liu X; Huang S; Jiang X; Baharin N; Fischer PM; Wang S
    Eur J Med Chem; 2013; 70():447-55. PubMed ID: 24185375
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Novel acylureidoindolin-2-one derivatives as dual Aurora B/FLT3 inhibitors for the treatment of acute myeloid leukemia.
    Jagtap AD; Chang PT; Liu JR; Wang HC; Kondekar NB; Shen LJ; Tseng HW; Chen GS; Chern JW
    Eur J Med Chem; 2014 Oct; 85():268-88. PubMed ID: 25089810
    [TBL] [Abstract][Full Text] [Related]  

  • 76. Discovery of 6-(2-(dimethylamino)ethyl)-N-(5-fluoro-4-(4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole-6-yl)pyrimidin-2-yl)-5,6,7,8-tetrahydro-1,6-naphthyridin-2-amine as a highly potent cyclin-dependent kinase 4/6 inhibitor for treatment of cancer.
    Shi C; Wang Q; Liao X; Ge H; Huo G; Zhang L; Chen N; Zhai X; Hong Y; Wang L; Han Y; Xiao W; Wang Z; Shi W; Mao Y; Yu J; Xia G; Liu Y
    Eur J Med Chem; 2019 Sep; 178():352-364. PubMed ID: 31200237
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Discovery of a series of dihydroquinoxalin-2(1H)-ones as selective BET inhibitors from a dual PLK1-BRD4 inhibitor.
    Hu J; Wang Y; Li Y; Xu L; Cao D; Song S; Damaneh MS; Wang X; Meng T; Chen YL; Shen J; Miao Z; Xiong B
    Eur J Med Chem; 2017 Sep; 137():176-195. PubMed ID: 28586718
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Discovery of the selective and efficacious inhibitors of FLT3 mutations.
    Zhi Y; Li B; Yao C; Li H; Chen P; Bao J; Qin T; Wang Y; Lu T; Lu S
    Eur J Med Chem; 2018 Jul; 155():303-315. PubMed ID: 29894944
    [TBL] [Abstract][Full Text] [Related]  

  • 79.
    Zhang H; Xu L; Qin X; Chen X; Cong H; Hu L; Chen L; Miao Z; Zhang W; Cai Z; Zhuang C
    J Med Chem; 2019 Jul; 62(14):6665-6681. PubMed ID: 31095385
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Discovery of Novel 3-Quinoline Carboxamides as Potent, Selective, and Orally Bioavailable Inhibitors of Ataxia Telangiectasia Mutated (ATM) Kinase.
    Degorce SL; Barlaam B; Cadogan E; Dishington A; Ducray R; Glossop SC; Hassall LA; Lach F; Lau A; McGuire TM; Nowak T; Ouvry G; Pike KG; Thomason AG
    J Med Chem; 2016 Jul; 59(13):6281-92. PubMed ID: 27259031
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.